Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.00
Bid: 65.00
Ask: 69.00
Change: 0.00 (0.00%)
Spread: 4.00 (6.154%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 67.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Changes

13 Dec 2019 13:21

RNS Number : 8662W
NetScientific PLC
13 December 2019
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Board Changes

 

 

London, UK - 13 December 2019 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces planned changes to its Board of Directors. Barry Wilson will retire from the Board following seven years as Non-Executive Director. John Clarkson joins NetScientific as Non-Executive Director with immediate effect.

 

John brings more than twenty years of commercial expertise in leadership roles including that of CEO, Chairman and Non-Executive Director. He was previously partner in charge of a consultancy division in Cooper Deloitte (now PricewaterhouseCoopers), providing services to a range of blue-chip companies and was subsequently Vice Chairman of Laura Ashley Inc. John is an active investor in start-ups, high-tech and growing businesses.

 

John holds a MBA from Cranfield University, after qualifying as an accountant and is a fellow of the Association of Chartered Certified Accountants.

 

John Eric Clarkson (aged 70) currently holds or has held in the past 5 years the following directorships and partnerships:

Current directorships

Past directorships & partnerships

Heimdall Protective Tech Ltd

Recycling Technologies Ltd

Revival Car Hire Ltd

Wrens Cathedral Ltd

Fox Brothers (Elswick) Ltd

C & C Developments Fleetwood Ltd

Around Town @ Limited

C & C Property Developments Ltd

Development Financial and Management Services Limited

 

In addition, Mr. Clarkson was until 31 July 2019 a director of Wroxall Abbey Estate Limited, which was put in to administration on 22 October 2019. The process of administration is ongoing and the sale of assets of the Company is not finalised, and consequently the level of unsatisfied creditors is currently unknown.

 

No further disclosure is required under Paragraph (g) to Schedule Two of the AIM Rules for Companies.

 

Sir Richard Sykes, Chairman of NetScientific, said: "We would like to thank Barry for his significant contributions to the Company. He has provided great strategic insight and direction during his time on the Board and we wish him well for his future. At the same time, we are delighted to welcome John to NetScientific. His commercial experience will be extremely valuable as the Company continues to drive value for its shareholders."

 

# # #

 

For more information, please contact:

 

  NetScientific

Ian Postlethwaite, CEO / CFO

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666

MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977

 

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. 

 

For more information, please visit the website at www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOATJBJTMBBBBRL
Date   Source Headline
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.